- Home
- WRN vs ARVN Comparison
WRN vs ARVN Comparison
Compare WRN & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WRN | ARVN |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.2M | 600.2M |
| IPO Year | 2006 | 2018 |
Fundamental Metrics
Financial Performance| Metric | WRN | ARVN |
|---|---|---|
| Price | $2.54 | $8.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 19 |
| Target Price | $4.58 | ★ $15.05 |
| AVG Volume (30 Days) | ★ 901.6K | 539.8K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | N/A | ★ 1.70 |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.29 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.53 | $6.97 |
| 52 Week High | $4.26 | $14.22 |
Technical Indicators
Market Signals| Indicator | WRN | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 59.77 | 49.67 |
| Support Level | $2.28 | $8.96 |
| Resistance Level | $2.61 | $9.70 |
| Average True Range (ATR) | 0.10 | 0.33 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 80.00 | 10.24 |
Price Performance
Historical ComparisonAbout WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project). The Casino can deliver the critical minerals necessary for the energy transition while serving as an engine for long-term economic growth and prosperity in the North.
About ARVN Arvinas Inc.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.